Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2027

Conditions
SleepDeliriumICU Hospitalization
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine will be prepared at a concentration of 4 mcg/ml by diluting 200 mcg/2 ml vials with 48 mL of 0.9% normal saline to a total volume of 50 ml. A maintenance infusion of 0.2-1.2 mcg/kg/hr will be initiated to sustain the sedative effect and promote sleep throughout the trial period. ICU nurses are experienced in titrating dexmedetomidine for both patients on high flow oxygen (Optiflow) and intubated patients with delirium as part of routine care. The ICU bedside nurse will be responsible for using the lowest effective dose to achieve a Richmond Agitation Sedation Scale (RASS) of -2, up to a maximum of 1.2 mcg/kg/hr, while monitoring for adverse events such as bradycardia and hypotension.

OTHER

Control (placebo) group

The control group will receive an infusion of 0.9% saline at 5-45 ml/hr titrated to the lowest effective dose to achieve a RASS of -2 for two nights following randomization.

All Listed Sponsors
lead

University of Alberta

OTHER